

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 10 February 2021.

I am pleased to confirm the following.

Please see information requested below from MKUH during the period 19/11/2020 to 19/02/2021.

1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

| | |
|--|------------|
| • Atezolizumab | 0 Patients |
| • Carboplatin with Gemcitabine | 4 Patients |
| • Carboplatin with Paclitaxel | 0 Patients |
| • Carboplatin single or in any other combination | 0 Patients |
| • Cisplatin with Gemcitabine | 2 Patients |
| • Cisplatin single or in any other combination | 0 Patients |
| • Nivolumab | 0 Patients |
| • MVAC with G-CSF | 0 Patients |
| • Pembrolizumab | 0 Patients |
| • Any other regimen including Paclitaxel | 0 Patients |
| • Any other chemo regimen | 0 Patients |
| • Other active systemic anti-cancer therapy | 0 Patients |
| • Palliative care | 0 Patients |

2. Could you please provide the total number of patients with any treatment in the last three months for:

| | |
|--|-------------|
| • Total non-small cell lung cancer (NSCLC) | 59 Patients |
| • BRAF+ non-small cell lung cancer (NSCLC) | 0 Patients |

3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

| | |
|---|------------|
| • Afatinib | 6 Patients |
| • Alectinib | 0 Patients |
| • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel | 1 Patient |
| • Atezolizumab monotherapy | 2 Patients |
| • Bevacizumab | 0 Patients |
| • Brigatinib | 0 Patients |
| • Ceritinib | 0 Patients |

| | |
|---|-------------|
| • Crizotinib | 2 Patients |
| • Dacomitinib | 0 Patients |
| • Dabrafenib with Trametinib | 0 Patients |
| • Docetaxel | 0 Patients |
| • Durvalumab | 1 Patient |
| • Erlotinib | 3 Patients |
| • Gefitinib | 0 Patients |
| • Gemcitabine | 0 Patients |
| • Nintedanib with Docetaxel | 4 Patients |
| • Nivolumab | 0 Patients |
| • Osimertinib | 1 Patient |
| • Paclitaxel | 4 Patients |
| • Pembrolizumab chemo in combination | 7 Patients |
| • Pembrolizumab monotherapy | 17 Patients |
| • Pemetrexed with Carboplatin | 2 Patients |
| • Pemetrexed with Cisplatin | 1 Patient |
| • Vinorelbine and cisplatin/carboplatin | 1 Patient |

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

| |
|---|
| <p>Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.</p> |
|---|